BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Saima Mushtaq, Atika Mansoor, Muhammad Umar, Amjad Khan, Saima Siddiqi, Sobia Manzoor. Direct‐acting antiviral agents in the treatment of chronic hepatitis C—Real‐life experience from clinical practices in PakistanJournal of Medical Virology 2020; 92(12): 3475 doi: 10.1002/jmv.25745
2
Maissa El-Raziky, Marwa Khairy, Ahmed Fouad, Ahmed Salama, Aisha Elsharkawy, Omnia Tantawy. Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing RegimensJournal of Interferon & Cytokine Research 2018; 38(3): 129 doi: 10.1089/jir.2017.0137
3
In Soo Oh, Joung Won Won, Hyung Joon Kim, Hyun Woong Lee. Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infectionThe Korean Journal of Internal Medicine 2017; 32(6): 1010 doi: 10.3904/kjim.2016.405
4
Vijay Gayam, Muhammad Rajib Hossain, Mazin Khalid, Sandipan Chakaraborty, Osama Mukhtar, Sumit Dahal, Amrendra Kumar Mandal, Arshpal Gill, Pavani Garlapati, Sreedevi Ramakrishnaiah, Khalid Mowyad, Jagannath Sherigar, Mohammed Mansour, Smruti Mohanty. Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care SettingGut and Liver 2018; 12(6): 694 doi: 10.5009/gnl18004
5
N. K. T. Hlaing, R. A. Mitrani, S. T. Aung, W. W. Phyo, M. Serper, A. M. M. Kyaw, A. H. Bwa, K. M. Win, K. R. Reddy. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experienceJournal of Viral Hepatitis 2017; 24(11): 927 doi: 10.1111/jvh.12721
6
Hend Ibrahim Shousha, Yasmin Saad, Doa’a A. Saleh, Hosam Dabes, Magdy Alserafy, Yehia ElShazly, Mohamed Said. Simple predictors of nonresponse to direct-acting antivirals in chronic hepatitis C patientsEuropean Journal of Gastroenterology & Hepatology 2020; 32(8): 1017 doi: 10.1097/MEG.0000000000001612
7
Yousry Esam-Eldin Abo-amer, Rehab Badawi, Mohamed El-Abgeegy, Heba Fadl Elsergany, Ahmed Abdelhaleem Mohamed, Sahar Mohamed Mostafa, Hatem Samir Alegaily, Shaimaa Soliman, Sally Elnawasany, Sherief Abd-Elsalam. Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment FailureAdvances in Virology 2020; 2020: 1 doi: 10.1155/2020/9075905
8
Moisés Uriarte-Pinto, Herminia Navarro-Aznarez, Natalia De La Llama-Celis, Piedad Arazo-Garcés, Ana María Martínez-Sapiña, María Reyes Abad-Sazatornil. Effectiveness and security of chronic hepatitis C treatment in coinfected patients in real-worldInternational Journal of Clinical Pharmacy 2018; 40(3): 608 doi: 10.1007/s11096-018-0621-0
9
N. Bhardwaj, M. Ragonnet-Cronin, B. Murrell, K. Chodavarapu, R. Martin, S. Chang, M. D. Miller, J. J. Feld, M. Sulkowski, A. Mangia, J. O. Wertheim, A. Osinusi, J. McNally, D. Brainard, H. Mo, E. S. Svarovskaia. Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimensJournal of Viral Hepatitis 2018; 25(4): 344 doi: 10.1111/jvh.12825
10
Crina Fofiu, Alina Boeriu, Felicia Coman, Alexandru Fofiu, Nikola Panic, Milutin Bulajic, Daniela Dobru. Interferon-Free Regimen: Equally Effective in Treatment Naive and Experienced HCV PatientsAnnals of Hepatology 2019; 18(1): 137 doi: 10.5604/01.3001.0012.7905
11
Stephanie Popping, Valeria Cento, Federico García, Francesca Ceccherini-Silberstein, Carole Seguin-Devaux, David A.M.C. Vijver, Charles A. Boucher. The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis CJournal of Virus Eradication 2018; 4(3): 179 doi: 10.1016/S2055-6640(20)30267-3
12
Ayman Yosry, Rabab Fouad, Shereen A. Alem, Aisha Elsharkawy, Mohammad El-Sayed, Noha Asem, Ehsan Hassan, Ahmed Ismail, Gamal Esmat. FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infectionArab Journal of Gastroenterology 2016; 17(2): 78 doi: 10.1016/j.ajg.2016.05.002
13
Michael Bright Yakass, David Franco, Osbourne Quaye. Suppressors of Cytokine Signaling and Protein Inhibitors of Activated Signal Transducer and Activator of Transcriptions As Therapeutic Targets in Flavivirus InfectionsJournal of Interferon & Cytokine Research 2020; 40(1): 1 doi: 10.1089/jir.2019.0097
14
Stefan Zeuzem, Graham R. Foster, Stanley Wang, Armen Asatryan, Edward Gane, Jordan J. Feld, Tarik Asselah, Marc Bourlière, Peter J. Ruane, Heiner Wedemeyer, Stanislas Pol, Robert Flisiak, Fred Poordad, Wan-Long Chuang, Catherine A. Stedman, Steven Flamm, Paul Kwo, Gregory J. Dore, Gladys Sepulveda-Arzola, Stuart K. Roberts, Ruth Soto-Malave, Kelly Kaita, Massimo Puoti, John Vierling, Edward Tam, Hugo E. Vargas, Rafi Bruck, Francisco Fuster, Seung-Woon Paik, Franco Felizarta, Jens Kort, Bo Fu, Ran Liu, Teresa I. Ng, Tami Pilot-Matias, Chih-Wei Lin, Roger Trinh, Federico J. Mensa. Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 InfectionNew England Journal of Medicine 2018; 378(4): 354 doi: 10.1056/NEJMoa1702417
15
Lindsy Liu, Monika N. Daftary, Mohammad S. Alzahrani, Chiemena Ohanele, Mary K. Maneno. Barriers to the Treatment of Hepatitis C among Predominantly African American Patients Seeking Care in an Urban Teaching Hospital in Washington, D.C.Journal of the National Medical Association 2020;  doi: 10.1016/j.jnma.2020.08.006
16
L Milazzo, A Lai, E Calvi, P Ronzi, V Micheli, F Binda, AL Ridolfo, C Gervasoni, M Galli, S Antinori, S Sollima. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacyHIV Medicine 2017; 18(4): 284 doi: 10.1111/hiv.12429
17
Wendy Carter, Sarah Connelly, Kimberly Struble. Reinventing HCV Treatment: Past and Future PerspectivesThe Journal of Clinical Pharmacology 2017; 57(3): 287 doi: 10.1002/jcph.830
18
Christophe Hézode, Slim Fourati, Stéphane Chevaliez, Giovanna Scoazec, Alexandre Soulier, Anne Varaut, Murielle François, Isaac Ruiz, Françoise Roudot-Thoraval, Ariane Mallat, Jean-Michel Pawlotsky. Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral–Experienced Patients With Hepatitis CClinical Infectious Diseases 2017; 64(11): 1615 doi: 10.1093/cid/cix214
19
Mehmet Cabalak, Tayibe Bal, Yusuf Onlen, Mehmet Demir. Incidence and predictors of direct-acting antiviral treatment failure in Turkish patients with chronic hepatitis C genotype 1b infectionTropical Doctor 2020; 50(2): 141 doi: 10.1177/0049475519892082
20
Sarah Kattakuzhy, Eleanor Wilson, Sreetha Sidharthan, Zayani Sims, Mary McLaughlin, Angie Price, Rachel Silk, Chloe Gross, Elizabeth Akoth, Maryellen McManus, Benjamin Emmanuel, Shikha Shrivastava, Lydia Tang, Amy Nelson, Gebeyehu Teferi, Jose Chavez, Brian Lam, Hongmei Mo, Anuoluwapo Osinusi, Michael A. Polis, Henry Masur, Anita Kohli, Shyamasundaran Kottilil. Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti–Hepatitis C Virus Therapy in Patients With Advanced Liver DiseaseClinical Infectious Diseases 2015; : civ897 doi: 10.1093/cid/civ897
21
Simone Lanini, Paola Scognamiglio, Alessandra Mecozzi, Lorella Lombardozzi, Vincenzo Vullo, Mario Angelico, Antonio Gasbarrini, Gloria Taliani, Adolfo Francesco Attili, Carlo Federico Perno, Adriano De Santis, Vincenzo Puro, Fabio Cerqua, Gianpiero D’Offizi, Adriano Pellicelli, Orlando Armignacco, Francesco Saverio Mennini, Massimo Siciliano, Enrico Girardi, Vincenzo Panella, Giuseppe Ippolito. Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort studyBMC Infectious Diseases 2018; 18(1) doi: 10.1186/s12879-018-3125-6
22
Snezana Jovanovic-Cupic, Ana Bozovic, Milena Krajnovic, Nina Petrovic. Hepatitis C - From Infection to Cure2018;  doi: 10.5772/intechopen.76417
23
Onyema Ogbuagu, Ritche Hao, Michael Virata, Merceditas S. Villanueva, Maricar Malinis. Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patientsF1000Research 2017; 6: 620 doi: 10.12688/f1000research.11397.1
24
Jasmine Schulkind, Brian Stephens, Farsana Ahmad, Linda Johnston, Sharon Hutchinson, Donna Thain, Zoe Ward, Peter Vickerman, Matt Hickman, John F. Dillon. High response and re‐infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programmeJournal of Viral Hepatitis 2019; 26(5): 519 doi: 10.1111/jvh.13035
25
Radwa R. El-Tahan, Ahmed M. Ghoneim, Hosam Zaghloul. 5′ UTR and NS5B-based genotyping of hepatitis C virus in patients from Damietta governorate, EgyptJournal of Advanced Research 2018; 10: 39 doi: 10.1016/j.jare.2018.01.004
26
Mouna Rajhi, Kais Ghedira, Anissa Chouikha, Ahlem Djebbi, Imed Cheikh, Ahlem Ben Yahia, Amel Sadraoui, Walid Hammami, Msaddek Azouz, Nabil Ben Mami, Henda Triki, Jason Blackard. Phylogenetic Analysis and Epidemic History of Hepatitis C Virus Genotype 2 in Tunisia, North AfricaPLOS ONE 2016; 11(4): e0153761 doi: 10.1371/journal.pone.0153761
27
Valentina Pecoraro, Rita Banzi, Elisabetta Cariani, Johanna Chester, Erica Villa, Roberto D'Amico, Vittorio Bertele', Tommaso Trenti. New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled TrialsJournal of Clinical and Experimental Hepatology 2019; 9(4): 522 doi: 10.1016/j.jceh.2018.07.004
28
Christophe Hézode, Piero L. Almasio, Stefan Bourgeois, Peter Buggisch, Ashley Brown, Moises Diago, Yves Horsmans, Lawrence Serfaty, Ferenc Szalay, Giovanni B. Gaeta, Ramon Planas, Michael Schlag, Isabelle Lonjon-Domanec, Edmund Omoruyi, Ralph DeMasi, Stefan Zeuzem. Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver diseaseLiver International 2017; 37(9): 1304 doi: 10.1111/liv.13376
29
Kattareeya Kumthip, Niwat Maneekarn. The role of HCV proteins on treatment outcomesVirology Journal 2015; 12(1) doi: 10.1186/s12985-015-0450-x
30
Naveen Tmu, Ashish Kumar, Praveen Sharma, Vikas Singla, Naresh Bansal, Anil Arora. Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated CirrhosisJournal of Clinical and Experimental Hepatology 2019; 9(1): 4 doi: 10.1016/j.jceh.2018.02.009
31
Karina González-Aldaco, Luis A. Torres-Reyes, Claudia Ojeda-Granados, Alexis José-Ábrego, Nora A. Fierro, Sonia Román. Immunometabolic Effect of Cholesterol in Hepatitis C Infection: Implications in Clinical Management and Antiviral TherapyAnnals of Hepatology 2018; 17(6): 908 doi: 10.5604/01.3001.0012.7191
32
Tatyana Kushner, Douglas Dieterich, Behnam Saberi. Direct-acting antiviral treatment for patients with hepatocellular carcinomaCurrent Opinion in Gastroenterology 2018; 34(3): 132 doi: 10.1097/MOG.0000000000000431
33
Saima Mushtaq, Tayyab Saeed Akhter, Amjad Khan, Aamir Sohail, Arshad Khan, Sobia Manzoor. Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From PakistanFrontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.550205
34
Braira Wahid, Shazia Rafique, Komal Saleem, Amjad Ali, Muhammad Idrees. An Increase in Expression of SOCS1 Gene with Increase in Hepatitis C Virus Viral LoadJournal of Interferon & Cytokine Research 2018; 38(3): 122 doi: 10.1089/jir.2017.0129
35
Malik Sallam, Rawan Batarseh, Anas Natsheh, Jumana Abbadi, Esraa Al-Fraihat, Alaa’ Yaseen, Doaa Kaddomi, Nadia Khamees, Azmi Mahafzah, Gülşen Özkaya Şahin. An update on hepatitis C virus genotype distribution in Jordan: a 12-year retrospective study from a tertiary care teaching hospital in AmmanBMC Infectious Diseases 2020; 20(1) doi: 10.1186/s12879-019-4735-3
36
E A Klimova, E Z Burnevich, V P Chulanov, D A Gusev, O O Znoyko, S N Batskikh, S N Kizlo, N A Mamonova, E P Tarkhova, E N Krasavina, M Yu Samsonov, N D Yushchuk. Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis CTerapevticheskii arkhiv 2019; 91(8): 67 doi: 10.26442/00403660.2019.08.000384
37
Paula Eckardt, Jianli Niu, Angela Savage, Tara Griffin, Elizabeth Sherman. Effect of Health Insurance on Hepatitis C Sustained Virologic Response Rates to Sofosbuvir-Based Treatment Regimens in a South Florida Community HospitalJournal of the International Association of Providers of AIDS Care (JIAPAC) 2019; 18: 232595821983559 doi: 10.1177/2325958219835590
38
D. A. Lioznov, N. V. Dunaeva, N. H. Chung, O. V. Gorchakova, T. V. Antonova. Chronic hepatitis C: modern condition of the problemNephrology (Saint-Petersburg) 2019; 23(4): 36 doi: 10.24884/1561-6274-2019-23-4-36-46
39
Hirohito Yoneyama, Asahiro Morishita, Hisakazu Iwama, Koji Fujita, Takahiro Masaki, Joji Tani, Tomoko Tadokoro, Takako Nomura, Teppei Sakamoto, Kyoko Oura, Kei Takuma, Mai Nakahara, Shima Mimura, Akihiro Deguchi, Makoto Oryu, Kunihiko Tsutsui, Takashi Himoto, Kunitada Shimotohno, Takaji Wakita, Hideki Kobara, Tsutomu Masaki. Identification of microRNA associated with the elimination of hepatitis C virus genotype 1b by direct‐acting antiviral therapiesJournal of Gastroenterology and Hepatology 2020;  doi: 10.1111/jgh.15224
40
Courtney M. Boucher, Anne Walsh, Christopher P. Forest. Healing livers, saving livesJournal of the American Academy of Physician Assistants 2016; 29(5): 20 doi: 10.1097/01.JAA.0000482295.08412.4a
41
Zachary DeNardo, Minha Choi, Michelle Stiller, Dillon Buechel. Cost effectiveness of hepatitis C treatments: Need for a comprehensive evaluationThe Kaohsiung Journal of Medical Sciences 2017; 33(11): 584 doi: 10.1016/j.kjms.2017.06.007
42
Emma Gray, David J. Pasta, Suzanne Norris, Aisling O’Leary. Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registryBMC Health Services Research 2017; 17(1) doi: 10.1186/s12913-017-2188-1
43
Onyema Ogbuagu, Ritche Hao, Michael Virata, Merceditas S. Villanueva, Maricar Malinis. Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patientsF1000Research 2018; 6: 620 doi: 10.12688/f1000research.11397.2
44
Ramsha Khalid, Muhammad Faraz Anwar, Muhammad Aanish Raees, Sadaf Naeem, Syed Hani Abidi, Syed Ali. An in silico approach to analyze HCV genotype-specific binding-site variation and its effect on drug–protein interactionScientific Reports 2020; 10(1) doi: 10.1038/s41598-020-77720-9
45
Niels C Pedersen, Yunjeong Kim, Hongwei Liu, Anushka C Galasiti Kankanamalage, Chrissy Eckstrand, William C Groutas, Michael Bannasch, Juliana M Meadows, Kyeong-Ok Chang. Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitisJournal of Feline Medicine and Surgery 2018; 20(4): 378 doi: 10.1177/1098612X17729626
46
Lubomír Skladaný, Marian Oltman, Soňa Fraňková, Sylvia Dražilová, Petr Husa, Jan Šperl, Václav Hejda, Petr Urbánek, Svetlana Adamcová-Selčanová, Martin Janičko, Pavol Kristian, Viera Kupčová, Marek Rác, Ivan Schréter, Ladislav Virág, Adriana Liptáková, Miriam Ondrášová, Peter Jarčuška. Chronic hepatitis C virus infection in the Czech Republic and Slovakia: an analysis of patient and virus characteristicsInternational Journal of Public Health 2020; 65(9): 1723 doi: 10.1007/s00038-020-01496-y
47
Isabella Esposito, Sebastián Marciano, Leila Haddad, Omar Galdame, Alejandra Franco, Adrián Gadano, Diego Flichman, Julieta Trinks. Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus InfectionViruses 2018; 11(1): 3 doi: 10.3390/v11010003
48
Elisabete Andrade, Daniele Rocha, Marcela Fontana-Maurell, Elaine Costa, Marisa Ribeiro, Daniela Tupy de Godoy, Antonio G.P. Ferreira, Amilcar Tanuri, Patrícia Alvarez, Rodrigo Brindeiro. One-step real-time PCR assay for detection and quantification of RNA HCV to monitor patients under treatment in BrazilThe Brazilian Journal of Infectious Diseases 2018; 22(5): 418 doi: 10.1016/j.bjid.2018.08.003
49
Samira Basharkhah, Faezeh Sabet, Sanaz Ahmadi Ghezeldasht, Arman Mosavat, Hamid Reza Jahantigh, Elham Barati, Khosrow Shamsian, Masoud Saleh‐Moghaddam, Hiva Sharebyani, Tahereh Hassannia, Seyed Ali Akbar Shamsian. Prediction of HCV load using genotype, liver biomarkers, and clinical symptoms by a mathematical model in patients with HCV infectionMicrobiology and Immunology 2019; 63(11): 449 doi: 10.1111/1348-0421.12735
50
Fatemeh Sakhaee, Morteza Ghazanfari, Farzam Vaziri, Fatemeh Rahimi Jamnani, Mehdi Davari, Safoora Gharibzadeh, Roohollah Fateh, Farid Abdolrahimi, Shahin Pourazar Dizaji, Abolfazl Fateh, Seyed Davar Siadat. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infectionInfection, Genetics and Evolution 2017; 54: 330 doi: 10.1016/j.meegid.2017.07.023
51
Leon Tribolet, Emily Kerr, Christopher Cowled, Andrew G. D. Bean, Cameron R. Stewart, Megan Dearnley, Ryan J. Farr. MicroRNA Biomarkers for Infectious Diseases: From Basic Research to BiosensingFrontiers in Microbiology 2020; 11 doi: 10.3389/fmicb.2020.01197